.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Federal Trade Commission
Julphar
Accenture
McKesson
UBS
Covington
AstraZeneca
Deloitte

Generated: December 15, 2017

DrugPatentWatch Database Preview

OXYTROL FOR WOMEN Drug Profile

« Back to Dashboard

When do Oxytrol For Women patents expire, and when can generic versions of Oxytrol For Women launch?

Oxytrol For Women is a drug marketed by Allergan Sales Llc and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-one patent family members in twenty countries.

The generic ingredient in OXYTROL FOR WOMEN is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OXYTROL FOR WOMEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013► Subscribe► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OXYTROL FOR WOMEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,029,694Compositions and methods for transdermal oxybutynin therapy► Subscribe
8,241,662Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy► Subscribe
7,087,241Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OXYTROL FOR WOMEN

Country Document Number Estimated Expiration
Norway20161918► Subscribe
MexicoPA02010542► Subscribe
Brazil0315867► Subscribe
South Korea20120038026► Subscribe
World Intellectual Property Organization (WIPO)2004041187► Subscribe
China1438861► Subscribe
Australia5378201► Subscribe
Japan5770582► Subscribe
Cyprus1111498► Subscribe
Japan2003531157► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Novartis
Mallinckrodt
Daiichi Sankyo
Farmers Insurance
McKesson
Harvard Business School
Johnson and Johnson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot